Ibitta Enterprises Hires Consultant After GMP Inspection, Gets Warning Anyway
Executive Summary
Ibitta's response didn't provide sufficient documentation and other evidence indicating it will correct GMP problems found during FDA's May inspection. Warning also states some of firm's products are mis-branded, including stating information in two languages without repeating all required information in both languages.
You may also be interested in...
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.
Some Topical Analgesics Draw Outside US FDA’s Lines For Formulations And Indications
FDA warns six businesses found selling directly to consumers topical formulations containing lidocaine outside the 0.5% to 4% concentration range allowed under OTC monographs for topical analgesics